Cytoxan contains cyclophosphamide as its active ingredient. Cyclophosphamide is an alkylating agent used in oncology to treat a variety of malignant and autoimmune conditions. In Hong Kong, Cytoxan is a prescription-only medication regulated by the Department of Health.
The drug is supplied as oral pills, each containing 50 mg of cyclophosphamide. The formulation is intended for systemic use in patients whose treating physicians have determined that an alkylating chemotherapy regimen is appropriate.
Cyclophosphamide belongs to the class of alkylating agents. After oral absorption, it is metabolized in the liver by cytochrome P450 enzymes (mainly CYP2B6) into active phosphoramide mustard and acrolein metabolites.
Cyclophosphamide is approved in Hong Kong for several oncologic indications, as listed in the product label and the Hong Kong Department of Health’s drug formulary.
The drug is typically administered as part of multi-drug chemotherapy protocols; the exact regimen depends on tumor type, stage, and patient factors.
Patients should provide a complete medication and supplement list to their oncology team before starting Cytoxan.
Dosing must be individualized; the information above reflects general practice and does not replace professional medical advice.
This article provides educational information about Cytoxan and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Cytoxan is a brand name for the oral cyclophosphamide 50 mg tablet. Other brands may offer different strengths or formulations (e.g., intravenous). The active ingredient, pharmacology, and approved indications are the same across brands; only manufacturer and packaging differ.
Yes, cyclophosphamide can be taken with or without food. Many patients choose to take it with a small meal to reduce nausea, but the drug’s absorption is not significantly affected by food.
Nausea typically peaks within a few hours after dosing and often improves within 24 hours, especially when anti-emetic medication is used. Persistent nausea should be reported to the oncology team for possible dose adjustment.
Adequate hydration (at least 2 L of fluid daily) is recommended to dilute the acrolein metabolite and lower the risk of bladder toxicity. Some clinicians also advise a high-fluid intake on the days surrounding cyclophosphamide administration.
Blood in the urine may signal hemorrhagic cystitis. Increase fluid intake immediately and contact your healthcare provider; they may add mesna or adjust the treatment plan.
Herbal products that affect liver enzymes (e.g., St. John’s wort) could alter cyclophosphamide metabolism. Always disclose all supplements to your treating physician before starting therapy.
Reduced renal function can lead to higher concentrations of active metabolites. Dose reduction based on creatinine clearance is common, and close monitoring of kidney markers is essential.
Intravenous administration allows precise control of dosing and is preferred when rapid, high-dose exposure is needed, such as in certain conditioning regimens before bone-marrow transplantation.
Air travel is generally safe, but patients should stay hydrated, avoid dehydration, and carry a copy of their medication schedule in case medical assistance is needed during the flight.
Cyclophosphamide is a traditional chemotherapy with a broad mechanism affecting DNA. Targeted therapies act on specific molecular pathways and often have different side-effect profiles. Choice of therapy depends on cancer type, molecular markers, and the treating oncologist’s assessment.
